

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

**APPOINTMENT OF HONORARY CHAIRMAN,
APPOINTMENT OF EXECUTIVE DIRECTOR,
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND
CHANGE OF COMPANY SECRETARY AND AUTHORISED
REPRESENTATIVES**

The Board hereby announces the following changes of the Company all with effect from 22 August 2023:

1. Mr. Wang Yichuan has been appointed as the Honorary Chairman;
2. Mr. Liu Mingqing has been appointed as an executive Director and an authorised representative of the Company;
3. Mr. Pang Zhen has resigned as an authorised representative of the Company;
4. Mr. Gu Jianguo has been appointed as an independent non-executive Director, and a member of each of the Audit Committee, the Nomination Committee and the Remuneration Committee;
5. Ms. Shum Ching Yee Jennifer has resigned as the company secretary of the Company and ceased to act as an authorised representative of the Company; and
6. Mr. Hui Hung Kwan has been appointed as the company secretary of the Company and an authorised representative of the Company.

The board (the “**Board**”) of directors (“**Director(s)**”) of Life Healthcare Group Limited (the “**Company**”) is pleased to announce the followings:

APPOINTMENT OF HONORARY CHAIRMAN

The Board is pleased to announce that Mr. Wang Yichuan (“**Mr. Wang**”) has been appointed as the honorary chairman of the Company (the “**Honorary Chairman**”) for a term of 3 years with effect from 22 August 2023.

Mr. Wang, aged 43, obtained a Master degree of Business Administration from Oxford Business College in 2007. Mr. Wang was the managing director of Dongtai Capital Co. Ltd. *** from 2013 to 2020. Mr. Wang has acted as and is currently the chairman of Yichuan Holdings Limited*** since 2022. Mr. Wang has extensive experience in the field of finance and corporate governance.

As the Honorary Chairman, Mr. Wang does not have any management role in the Company. Mr. Wang is not required to participate in the meetings of the Board. He will not receive any fee during his tenure of office.

As at the date hereof, Mr. Wang does not hold (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications. Further, Mr. Wang has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and does not have any interests in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)(the “**SFO**”).

Save as disclosed above, there are no other matters relating to the appointment of Mr. Wang that need to be brought to the attention of the shareholders of the Company and there is no other information concerning Mr. Wang that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Liu Mingqing (“**Mr. Liu**”) has been appointed as the executive Director of the Company with effect from 22 August 2023. Mr. Liu has been appointed as the chief executive officer of the Company on 9 August 2023.

Mr. Liu, aged 44, obtained a Master degree in Economics from Tongji University in the People’s Republic of China in 2005. Mr. Liu has been serving as an executive director of Kiu Hung International Holdings Limited, a company listed on the Stock Exchange (Stock Code: 00381) since 27 March 2020. Mr. Liu has over 15 years of experience in financial and investment related business and considerable experience in securities and futures, corporate finance, derivative products and other various financial services.

Save as disclosed in this announcement, as at the date hereof, Mr. Liu does not hold (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Mr. Liu has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Listing Rules) and does not have any interests in the securities of the Company within the meaning of Part XV of the SFO.

Under the letter of appointment entered into between Mr. Liu and the Company, Mr. Liu's term of service is three years and subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The remuneration of Mr. Liu is HK\$700,000 per annum which is determined by the Board and the remuneration committee of the Company with reference to his experience, duties and responsibilities within the Company.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Liu that need to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Mr. Liu for joining the Board.

CHANGE OF AUTHORISED REPRESENTATIVE UNDER THE LISTING RULES AND COMPANIES ORDINANCE

The Board is pleased to announce that Mr. Pang Zhen (“**Mr. Pang**”), who is currently serving as an executive Director of the Company, has tendered his resignation as the authorised representative of the Company under Rule 3.05 of the Listing Rules (the “**Authorised Representative under the Listing Rules**”) and the authorised representative of the Company for acceptance of service of process or notice in Hong Kong on behalf of the Company in accordance with Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Authorised Representative under the Companies Ordinance**”), all with effect from 22 August 2023. Mr. Pang will continue to remain as an executive Director of the Company.

The Board also announces that Mr. Liu has been appointed as the Authorised Representative under the Listing Rules and the Authorised Representative under the Companies Ordinance, all with effect from 22 August 2023.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Gu Jianguo (“**Mr. Gu**”) has been appointed as an independent non-executive Director, and a member of each of the audit committee of the Company (“**Audit Committee**”), the nomination committee of the Company (“**Nomination Committee**”) and the remuneration committee of the Company (“**Remuneration Committee**”) with effect from 22 August 2023.

Mr. Gu, aged 40, has over 18 years of experience in project and administrative management and has extensive expertise in operation and production of glass and materials related products. Mr. Gu was the executive Director of Sunlight Technology Holdings Limited, a company listed on the Stock Exchange (Stock Code: 1950) from 10 December 2021 to 3 March 2023. From 2003 to 2012, Mr. Gu was an executive deputy general manager of Nanjing Yaopi Network Technology Co., Limited*** (formerly known as Nanjing Yaopi Glass Co., Limited***). Since 2014, Mr. Gu has worked as a general manager at Hongze Hetai Investment Co., Limited***. Mr. Gu completed a senior management program from the Business School of Nanjing Normal University.

Save as disclosed in this announcement, as at the date hereof, Mr. Gu does not hold (i) any other position in the Company and other members of the Group; (ii) any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As the date of this announcement, Mr. Gu has no relationships with any Directors, senior management, substantial or controlling shareholders of the Company (having the meaning ascribed to it in the Listing Rules) and does not have any interests in the securities of the Company within the meaning of Part XV of the SFO.

Under the letter of appointment entered into between Mr. Gu and the Company, Mr. Gu's term of service is three years. His directorship in the Company is subject to rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. The remuneration of Mr. Gu is HK\$20,000 per month which is determined by the Board and the Remuneration Committee with reference to his experience, duties and responsibilities within the Company.

Mr. Gu confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, there are no other matters relating to the appointment of Mr. Gu that need to be brought to the attention of shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express a warm welcome to Mr. Gu for joining the Board.

The Board would also like to update the shareholders of the Company that, with the appointment of Mr. Gu as an independent non-executive Director, the Company has complied with Rule 3.10(1) of the Listing Rules. However, the Company is still actively searching for potential candidates with the appropriate professional qualifications or accounting or related financial management expertise to fill the vacancy of an independent non-executive Director and the chairman of the Audit Committee. The Board will make its best endeavours to identify a suitable candidate to fill such vacancy as soon as practicable and before 30 September 2023 to comply with the requirements under Rules 3.10(2) and 3.21 of the Listing Rules. For further details, please refer to the Company's announcement dated 18 July 2023.

CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE

The Board announces that Ms. Shum Ching Yee Jennifer (“**Ms. Shum**”) has tendered her resignation as the company secretary of the Company (the “**Company Secretary**”), the Authorised Representative under the Listing Rules, and the Authorised Representative under the Companies Ordinance, all with effect from 22 August 2023.

Ms. Shum has confirmed that she has no disagreement with the Board, and there are no matters in relation to her resignation from the above positions that need to be brought to the attention of the shareholders of the Company.

The Board also announces that in replacement of Ms. Shum, Mr. Hui Hung Kwan (“**Mr. Hui**”) has been appointed as the Company Secretary, the Authorised Representative under the Listing Rules and the Authorised Representative under the Companies Ordinance, all with effect from 22 August 2023.

Mr. Hui is a member of the Hong Kong Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants. He obtained a Bachelors’ Degree in Business Administration from the Chinese University of Hong Kong.

The Board would like to take this opportunity to welcome Mr. Hui to join the Company.

By order of the Board
Life Healthcare Group Limited
Wang Mengyao
Executive Director

Hong Kong, 22 August 2023

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Wang Mengyao
Mr. Liu Mingqing
Mr. Yuan Limin
Mr. Man Wai Lun
Mr. Pang Zhen

Independent non-executive Directors:

Mr. Gu Jianguo
Dr. Wang, Bruce Xianliang
Dr. Zhao, Shawn Xiaohong

*** *For identification purpose only. If there is any inconsistency between the Chinese names of the entities and their English translations, the Chinese version shall prevail.*